Finoriq research workspace
Atea Pharmaceuticals, Inc. (AVIR) Historical Metrics
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops. Review AVIR valuation ratios, fundamentals, and filing metrics on Finoriq.
Company Snapshot
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
- Company
- Atea Pharmaceuticals, Inc. (AVIR)
- Ticker
- AVIR
- Market Cap
- $385.3M
- Latest Price
- $4.815
- Industry
- Biotech & Pharma
Atea Pharmaceuticals, Inc. (AVIR) Current Valuation Metrics
Static valuation preview for Atea Pharmaceuticals, Inc. (AVIR). Market data retrieved 2026-07-09. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| Earnings YieldLatest TTM net income divided by market cap. | -43.3% | Net Income | TTM Q1 2026 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -37.8% | Operating Cash Flow | TTM Q1 2026 |
| Price / BookMarket cap divided by stockholders' equity. | 1.67x | Stockholders' Equity | Q1 2026 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.